Literature DB >> 9367218

Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.

P de Bruijn1, J Verweij, W J Loos, K Nooter, G Stoter, A Sparreboom.   

Abstract

Sensitive high-performance liquid chromatographic assays have been developed to determine the levels of the lactone and lactone plus carboxylate (total) forms of the antitumor agent irinotecan (CPT-11) and its active metabolite SN-38, in human plasma. The related compound camptothecin was used as the internal standard. The selective sample pretreatment for the lactone forms involved a single solvent extraction with acetonitrile-n-butyl chloride (1:4, v/v), whereas the sample clean-up for the total forms was a simple protein precipitation with aqueous perchloric acid-methanol (1:1, v/v), which results in the conversion of the carboxylate to the lactone forms. Chromatography was carried out on a Hypersil ODS column, with detection performed fluorimetrically. The methods have been validated, and stability tests under various conditions have been performed. The lower limits of quantitation are 0.5 and 2.0 ng/ml for the lactone and total forms, respectively. The assays have been used in a single pharmacokinetic experiment in a patient to investigate the applicability of the method in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367218     DOI: 10.1016/s0378-4347(97)00290-9

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  8 in total

1.  Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

Authors:  Xiaohong Chen; Cody J Peer; Raul Alfaro; Tian Tian; Shawn D Spencer; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2012-01-16       Impact factor: 3.935

2.  Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Authors:  D J Crona; J Ramirez; W Qiao; A-J de Graan; M J Ratain; R H N van Schaik; R H J Mathijssen; G L Rosner; F Innocenti
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

Review 3.  Oral topoisomerase 1 inhibitors in adult patients: present and future.

Authors:  H A Gelderblom; M J DE Jonge; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  Quantitative determination of irinotecan and the metabolite SN-38 by nanoflow liquid chromatography-tandem mass spectrometry in different regions of multicellular tumor spheroids.

Authors:  Xin Liu; Amanda B Hummon
Journal:  J Am Soc Mass Spectrom       Date:  2015-01-21       Impact factor: 3.109

5.  Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.

Authors:  Sander A Huisman; Peter de Bruijn; Inge M Ghobadi Moghaddam-Helmantel; Jan N M IJzermans; Erik A C Wiemer; Ron H J Mathijssen; Ron W F de Bruin
Journal:  Br J Pharmacol       Date:  2016-02-08       Impact factor: 8.739

6.  Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Authors:  Smitha S Krishnamurthi; Joanna M Brell; Charles L Hoppel; Merrill J Egorin; Karen C Weaver; Xiaolin Li; Stephen T Ingalls; Eleanor G Zuhowski; Mark D Schluchter; Afshin Dowlati; Matthew M Cooney; Joseph Gibbons; Beth A Overmoyer; S Percy Ivy; Scot C Remick
Journal:  Cancer Chemother Pharmacol       Date:  2008-04-15       Impact factor: 3.333

7.  Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Authors:  R H J Mathijssen; J Verweij; W J Loos; P de Bruijn; K Nooter; A Sparreboom
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

Review 8.  The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.

Authors:  Daniel R Principe; Patrick W Underwood; Murray Korc; Jose G Trevino; Hidayatullah G Munshi; Ajay Rana
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.